Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries

被引:66
作者
DeRoeck, D [1 ]
Deen, J [1 ]
Clemens, JD [1 ]
机构
[1] Int Vaccine Inst, Seoul 151600, South Korea
关键词
dengue/dengue haemorrhagic fever; vaccines; policymaking;
D O I
10.1016/S0264-410X(03)00533-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A survey of policyrnakers and other influential professionals in four southeast Asian countries (Cambodia, Indonesia, Philippines and Vietnam) was conducted to determine policyrnakers' views on the public health importance of dengue fever and dengue haemorrhagic fever (DHF), the need for a vaccine and the determinants influencing its potential introduction. The survey, which involved face-to-face interviews with policyrnakers, health programme managers, researchers, opinion leaders and other key informants, revealed an almost uniformly high level of concern about dengue fever/DHF and a high perceived need for a dengue vaccine. Several characteristics of the disease contribute to this high sense of priority, including its geographic spread, occurrence in outbreaks, the recurrent risk of infection each dengue season, its severity and the difficulty in diagnosis and management, its urban predominance, its burden on hospitals, and its economic toll on governments and families. Research felt to be key to future decision-making regarding dengue vaccine introduction include: disease surveillance studies, in-country vaccine trials or pilot projects, and studies on the economic burden of dengue and the cost-effectiveness of dengue vaccines. The results suggest favourable conditions for public and private sector markets for dengue vaccines and the need for creative financing strategies to ensure their accessibility to poor children in dengue-endemic countries. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:121 / 129
页数:9
相关论文
共 27 条
[1]  
[Anonymous], 1999, STRENGTH IMPL GLOB S
[2]   Live attenuated tetravalent dengue vaccine [J].
Bhamarapravati, N ;
Sutee, Y .
VACCINE, 2000, 18 :44-47
[3]  
Cardosa MJ, 1998, BRIT MED BULL, V54, P395, DOI 10.1093/oxfordjournals.bmb.a011696
[4]  
DEROECK D, POLICYMAKERS VIEWS R
[5]   Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region [J].
Durbin, AP ;
Karron, RA ;
Sun, W ;
Vaughn, DW ;
Reynolds, MJ ;
Perreault, JR ;
Thumar, B ;
Men, R ;
Lai, CJ ;
Elkins, WR ;
Chanock, RM ;
Murphy, BR ;
Whitehead, SS .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2001, 65 (05) :405-413
[6]   A LIVE ATTENUATED DENGUE-1 VACCINE CANDIDATE (45AZ5) PASSAGED IN PRIMARY DOG KIDNEY-CELL CULTURE IS ATTENUATED AND IMMUNOGENIC FOR HUMANS [J].
EDELMAN, R ;
TACKET, CO ;
WASSERMAN, SS ;
VAUGHN, DW ;
ECKELS, KH ;
DUBOIS, DR ;
SUMMERS, PL ;
HOKE, CH .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (06) :1448-1455
[7]  
Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
[8]   Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine [J].
Guirakhoo, F ;
Arroyo, J ;
Pugachev, KV ;
Miller, C ;
Zhang, ZX ;
Weltzin, R ;
Georgakopoulos, K ;
Catalan, J ;
Ocran, S ;
Soike, K ;
Ratterree, M ;
Monath, TP .
JOURNAL OF VIROLOGY, 2001, 75 (16) :7290-7304
[9]  
HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
[10]   The future of dengue vaccines [J].
Halstead, SB ;
Deen, J .
LANCET, 2002, 360 (9341) :1243-1245